BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 26
• 27
• 28
• 29
• 30

• Drug Development

  Rexahn Pharmaceuticals, Inc. Presents Preliminary Efficacy Data From The Ongoing Phase IIa Clinical Trial Of RX-3117 In Metastatic Bladder Cancer At The ASCO 2017 Annual Meeting

  June 5, 2017

   · 

  9 min read
• Drug Development

  Radius Health Presents Positive Data From A Fully Enrolled Ongoing Phase I Study For Investigational Drug Elacestrant (RAD1901) At The 2017 ASCO

  June 5, 2017

   · 

  7 min read
• Drug Development

  Five Prime Presents Initial Clinical Trial Data From Phase I/II Trial Of Cabiralizumab In Pigmented Villonodular Synovitis (PVNS) At 2017 ASCO Annual Meeting

  June 5, 2017

   · 

  5 min read
• Biotech Bay

  European Patent Office Maintains FibroGen Patent Relating To Hypoxia-Inducible Factor (HIF) Prolyl Hydroxylase Inhibitor Technology

  June 5, 2017

   · 

  5 min read
• Drug Development

  ZIOPHARM Oncology Announces Positive Updated Results Of Ad-RTS-Hil-12 + Veledimex In Recurrent Glioblastoma At The 2017 ASCO Annual Meeting

  June 5, 2017

   · 

  8 min read
• Drug Development

  Avivagen Provides Business Updates

  June 5, 2017

   · 

  12 min read
• Drug Development

  Janssen-Cilag International NV Release: Abiraterone Acetate Provided Significant Clinical Benefit In Patients With High-Risk Metastatic Hormone-Naïve Prostate Cancer (mHNPC), Improving Overall Survival And Radiographic Progression-Free Survival

  June 5, 2017

   · 

  14 min read
• Drug Development

  BeiGene Presents Initial Phase I Data On Anti-PD-1 Antibody BGB-A317 Combined With PARP Inhibitor BGB-290 At The 2017 ASCO Annual Meeting

  June 5, 2017

   · 

  7 min read
• Drug Development

  SCYNEXIS, Inc. Release: Eight Presentations At ASM Microbe 2017 Further Highlight The Strong Antifungal Effect And Promising Safety Profile Of Lead Anti-Infective Candidate SCY-078

  June 5, 2017

   · 

  6 min read
• Business

  Novan Announces Leadership Adjustments And Business Update

  June 5, 2017

   · 

  7 min read